EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice

B Butrón-Bris, M Llamas-Velasco, M C Ovejero-Benito, J Santos-Juanes, A Martínez-López, R Ruiz-Villaverde, G Roustan, O Baniandrés, R Izu-Belloso, P de la Cueva, A Sahuquillo-Torralba, A Gónzalez-Quesada und 9 weitere

Experimental Dermatology · 2024-08 · 33 (8)

DOI: 10.1111/exd.15152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, online erschienen am 30.07.2024. Verfasst von B Butrón-Bris und 20 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Instituto de Investigación Sanitaria La Princesa, Hospital Universitario de la Princesa, Madrid, Spain. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real‐life clinical practice. Ninety patients with plaque psoriasis recruited from—Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR 27 years) and weight (>76 kg) were associated with treatment response; after correcting by these factors, no association (FDR >0.15) was found for any polymorphism and response to tildrakizumab at 6 months. The analysis at 12 months identified the genotype GG for rs610604 ( TNFAIP3 ), CT for rs9373839 ( ATG5 ), and delCTGT/delCTGT for rs72167053 ( PDE4D ) as risk factors to not achieve an optimal response (PASI ≤1), while CT for rs708567 ( IL17RC ) was protective, independently of weight and disease duration (FDR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedHumansFemaleMaleMiddle AgedAdultPolymorphism, Single NucleotideTreatment OutcomeGenotypeAgedPolymorphism, Genetic

Stichwörter der Autor:innen

effectivenessgenetic variantspsoriasistildrakizumab

Substanzen

tildrakizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Servicio de Dermatología, Instituto de Investigación Sanitaria La Princesa, Hospital Universitario de la Princesa, Madrid, Spain.
  • Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU, CEU Universities Madrid, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario Central de Asturias, Asturias, Spain.
  • Grupo de Investigación en Dermatología (GRIDER), Universidad de Oviedo, Oviedo, Spain.
  • Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.

ORCID-Profile: H de la Fuente

Zitieren

APA

Butrón-Bris, B., Llamas-Velasco, M., Ovejero-Benito, M. C., Santos-Juanes, J., Martínez-López, A., Ruiz-Villaverde, R., Roustan, G., Baniandrés, O., Izu-Belloso, R., de la Cueva, P., Sahuquillo-Torralba, A., Gónzalez-Quesada, A., Vilarrasa-Rull, E., Pujol-Montcusí, J., García-Martínez, J., Navares, M., Palomar-Moreno, I., Novalbos, J., Abad-Santos, F., …, & de la Fuente, H. (2024). Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice. Experimental Dermatology, 33(8). https://doi.org/10.1111/exd.15152

Vancouver

Butrón-Bris B, Llamas-Velasco M, Ovejero-Benito MC, Santos-Juanes J, Martínez-López A, Ruiz-Villaverde R, et al. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice. Experimental Dermatology. 2024;33(8). doi:10.1111/exd.15152

BibTeX
@article{ButrnBris2024,
  author = {Butrón-Bris, B and Llamas-Velasco, M and Ovejero-Benito, M C and Santos-Juanes, J and Martínez-López, A and Ruiz-Villaverde, R and Roustan, G and Baniandrés, O and Izu-Belloso, R and de la Cueva, P and Sahuquillo-Torralba, A and Gónzalez-Quesada, A and Vilarrasa-Rull, E and Pujol-Montcusí, J and García-Martínez, J and Navares, M and Palomar-Moreno, I and Novalbos, J and Abad-Santos, F and Daudén, E and de la Fuente, H},
  title = {Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice},
  journal = {Experimental Dermatology},
  year = {2024},
  volume = {33},
  number = {8},
  doi = {10.1111/exd.15152}
}
Kostenlos starten →